Sky Century Investment (SKYI) Income towards Parent Company (2024 - 2026)
Sky Century Investment's (SKYI) quarterly Income towards Parent Company came in at -$4347.0 in Q2 2026, up 66.68% year-on-year from -$2608.0 in Q2 2025, and down 173.52% on a QoQ basis from $5913.0 in Q1 2026.
Sky Century Investment (SKYI) Income towards Parent Company (2024 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 3 years of Income towards Parent Company data on file, last reported at -$4347.0 in Q2 2026.
- On a quarterly basis, Income towards Parent Company rose 66.68% year-over-year to -$4347.0 in Q2 2026; TTM through May 2026 was -$62452.0, a 34.97% increase from a year earlier, with the FY2025 full-year figure at -$117225.0, down 60.76% from the prior year.
- Income towards Parent Company for Q2 2026 stood at -$4347.0, down from $5913.0 in the prior quarter.
- Over the last five years, Income towards Parent Company for SKYI reached as high as $5913.0 in Q1 2026 and fell as low as -$41628.0 in Q4 2024.
- Historically, Income towards Parent Company has averaged -$20853.7 across 3 years, with a median of -$20677.5 in 2024.
- Across the five-year window, Income towards Parent Company plunged 145.07% in 2025 and surged 122.11% in 2026, its largest moves.
- Year by year, Income towards Parent Company stood at -$41628.0 in 2024, then jumped by 32.23% to -$28213.0 in 2025, then surged by 84.59% to -$4347.0 in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$4347.0 in Q2 2026, $5913.0 in Q1 2026, and -$28213.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Sky Century Investment | 944,514.46 | 944,250.46 | 26,045.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -4,347.00 |
| Feb 28, 2026 | 5,913.00 |
| Nov 30, 2025 | -28,213.00 |
| Aug 31, 2025 | -35,805.00 |
| May 31, 2025 | -13,047.00 |
| Feb 28, 2025 | -26,745.00 |
| Nov 30, 2024 | -41,628.00 |
| Aug 31, 2024 | -14,610.00 |
| May 31, 2024 | -14,149.00 |
| Feb 29, 2024 | -35,906.00 |